Flow cytometry has aided in new and significant approaches to oncology and hematology therapeutics, including immunotherapy treatments. In this final instalment of our Illuminating Flow Cytometry series, we focus on the use of flow cytometry in oncology clinical trials and how it may provide the basis for treatment selection in the future.
Barry van der Strate is Director of Bioanalytical Science at PRA Health Sciences’ state-of-the-art Bioanalytical Laboratory in Assen, the Netherlands. Barry joined PRA in 2008 as a Project Manager and currently leads the Science Department for Immunoassays. Barry’s field of expertise is the development of immunoassays for PK, PD, ADA and flow cytometry purposes.
Get in touch with us for more information!